Abstract Background and Objectives This study aimed to evaluate the prognostic value of aberrant right hepatic artery (A‐RHA) involvement in patients with pancreatic cancer (PC). Methods This study enrolled 474 patients who underwent upfront pancreatectomy or neoadjuvant treatment for resectable (R) or borderline resectable (BR) PC from four institutions. The patients were divided into three groups: A‐RHA involvement group (n = 12), patients who had sole A‐RHA involvement without major arterial involvement; BR‐A group (n = 104), patients who had major arterial involvement; R/BR‐PV group (n = 358), others. Results All patients in the A‐RHA involvement group underwent margin‐negative resection. The median overall survival of the entire cohort in the A‐RHA involvement, R/BR‐PV, and BR‐A groups was 41.2, 33.5, and 25.2 months, respectively. Although survival in the R/BR‐PV group was significantly more favorable than that in the BR‐A group ( p = 0.0003), no significant difference was observed between the A‐RHA involvement group and the R/BR‐PV ( p = 0.7332) and BR‐A ( p = 0.1485) groups. Conclusions The prognosis of patients with PC and sole A‐RHA involvement was comparable to that of patients with R/BR‐PV.

Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study